Daewoong Pharmaceutical And Hanall Biopharma Invest In Turn Biotechnologies To Expand Growth Initiative

Apr 11, 2022•over 3 years ago

SeoulBiotechnologyHealth Care

Description

Daewoong Pharmaceutical (KRX: 069620.KS) and HanAll Biopharma (KRX: 009420.KS) today announced expansion of their open collaboration strategy by investing in Turn Biotechnologies, a Silicon Valley based company focused on developing novel mRNA medicines. The companies are supporting Turn Bio's continued development of a high-potential platform and are considering future long-term collaborations.

Company Information

Company

Turn Biotechnologies

Location

Seoul, Seoul, South Korea

About

Turn Bio is a pre-clinical-stage company focused on repairing tissue at the cellular level. The company's proprietary mRNA platform technology, ERATM, restores optimal gene expression by combatting the effects of aging in the epigenome. This restores the cells' ability to prevent or treat disease, and heal or regenerate tissue and will help to fight incurable chronic diseases. Turn Bio's technology provides a platform from which to attack a variety of now incurable chronic diseases. The company is currently completing pre-clinical research on tailored therapies targeting indications in dermatology and immunology, as well as developing therapies for ophthalmology, osteo-arthritis and the muscular system. For more information, see turn.bio or contact Jim Martinez, rightstorygroup / jim@rightstorygroup.com or (312) 543-9026.